NCT04261218View on ClinicalTrials.gov

Safety, Pharmacodynamics, Pharmacokinetics, and Efficacy of Tomivosertib Combined With Paclitaxel in Advanced Breast Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

August 25, 2020

Primary Completion Date

July 4, 2022

Study Completion Date

July 4, 2022

Conditions
Breast Cancer
Interventions
DRUG

tomivosertib

Tomivoserib is supplied as a 100 mg capsule, to be taken orally.

DRUG

paclitaxel

Taken weekly according to the current market label in combination with experimental tomivosertib.

Trial Locations (3)

T6G 1Z2

Cross Cancer Institute, Edmonton

V5Z 4E6

British Columbia Cancer Vancouver, Vancouver

H3T 1E2

Jewish General Hospital, Montreal

Sponsors

Collaborators (1)

Effector Therapeutics
All Listed Sponsors
collaborator

Effector Therapeutics

INDUSTRY

collaborator

Stand Up To Cancer

OTHER

lead

Translational Research in Oncology

OTHER